ArticleJournal of natural medicines2026
The root bark of Paeonia suffruticosa alleviates Staphylococcus aureus-induced pneumonia in mice by modulating toxin secretion and function.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Staphylococcus aureus, which is a major zoonotic pathogen, can cause various tissues infection and the prevalence of multidrug-resistant S. aureus causes more difficulty in treating the infectious diseases. Moutan Cortex (MC), tree peony root-bark, derived from the root bark of Paeonia suffruticosa Andrews, a key component in traditional Chinese herbal medicine for infections, inhibits α-hemolysin (Hlα) hemolytic activity of S. aureus. This study aimed to elucidate the characteristics of Hlα inhibition and the anti-inflammatory mechanisms of the herb Moutan Cortex decoction (MCD, the aqueous extract of MC). LC-MS identified active components including paeonol, paeoniflorin, glabrone, and ellagic acid. Network pharmacology predicted anti-inflammatory effects via modulation of MAPK-NF-κB and IL-1β signaling pathways. Animal studies demonstrated that MCD significantly reduced Hlα accumulation in lung tissue, suppressed NF-κB signaling-mediated inflammation, attenuated alveolar damage, and improved lung function in a murine model of S. aureus pneumonia. Bacterial proteomic analysis revealed that MCD, at a non-bactericidal concentration, downregulated the toxin synthesis-associated agr and SarA regulatory pathways, inhibited toxin secretion, and induced oxidative stress in S. aureus. Furthermore, MCD directly interacted with Hlα, inhibiting its oligomerization and blocking its hemolytic activity. These findings demonstrate that MCD exerts multi-targeted regulatory effects against S. aureus infection. At a sub-inhibitory concentration, it reduces bacterial pathogenicity both by interfering with the agr/SarA regulatory systems to diminish toxin secretion and by directly neutralizing secreted Hlα toxin, while concurrently alleviating lung injury by suppressing NF-κB signaling-mediated inflammation.
Indexed as
Identifiers
42014591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.